Great to see companies doing this, and credit to the research team for their robust protocols (often not the case with some of the super shoe studies that have been coming out). This is a group that we can have a lot of confidence in the validity of the observations.
But, one very important thing to remember about this is that the study compared the new shoes to 3 super shoes that we don’t have prior comparative data on.
I’ve done lab testing on the new Alphafly 3 in one athlete, and it was inferior to the Vaporfly 3 (~1.5% worse). I know of two other labs who had analogous findings in single athletes. Not a full study, but some consistent pilot smoke. Additionally, a friend and collaborator, Dustin Joubert/@labratrundown, did a nice mini case series with the Adidas Pro Evo, and for 2 of the 3 athletes it was discernibly worse than other super shoes. I’ve also tested the first iteration of the Fast-R shoes, and they were no different than control flats. I imagine the 2s they used here improved, but there’s some context.
It’s important to remember that some of these new shoes like the Alphafly 3 may not be better, and may in fact be worse (as has been the case in our limited observation). Just because an athlete runs fast in a shoe doesn’t mean the shoe helped, and it doesn’t exclude the possibility that the shoe even held them back a bit (relative to other offerings on the market).
I get why the research team used those two shoes, Alphafly 3 and Adidas Pro Evo as marathon WR shoes, but it would have been great to have a shoe like the Vaporfly for which we have a lot of historical data/publications to compare against (and for context, all iterations of the VF have tested very consistently in my experience).
I only add that information to remind us that the difference of the new Puma shoes relative to the “best” (ie, generalizably best) super shoes may not be 3.5%, but could no doubt still be substantially better (1.0-2.5%) than something like the Vaporfly series. Ie, it can be true both that they’re 3.5% better than the AF3s and Evo Pros, but a little bit less than that relative to other shoes on the market. I really would love a larger study on those shoes relative to old flats and/or the Vaporfly.
I’d commend Puma on (a) pushing the envelope in the design and development processes and (b) promptly publishing data to back up marketing claims. It would be great to see companies consistently follow suit.
I’ll be honest - I figured there was certainly room to continue to improve within the design space (ie, the stack height limitation), but even a consistent 2-2.5% improvement past the benefit of the current form of super shoes (3-3.5% or so) was the upper ends of what I figured was feasible in that space, and thought that was a few years away. It’ll be interesting to see if this evolves further. I’m very curious about Saucony’s new shoe, as they seem to also be using a new foam with even better compliance and resilience as well. I suspect individualization of the architecture is the next frontier - it would be great to develop and validate field tests for individuals without access to labs.